Long-term antipsychotics do not increase risk of MI or stroke
- PDF / 169,821 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 6 Downloads / 173 Views
1
Long-term antipsychotics do not increase risk of MI or stroke Long-term antipsychotic therapy does not appear to increase the risk of myocardial infarction (MI) or stroke, but some antipsychotics (APs) may increase the risk of cardiovascular (CV) death, according to findings of a meta-analysis published in European Neuropsychopharmacology. Medline and Embase were searched for randomised controlled trials published up to December 2017 which evaluated APs compared with other APs or placebo over a period of one year or longer in patients with bipolar disorder or shizophrenia. The APs investigated included aripiprazole, fluphenazine, haloperidol, paliperidone, quetiapine, risperidone, sertindole and ziprasidone. In total, 92 trials met the inclusion criteria for meta-analysis; 24 of these reported the incidence of CV death, 11 reported MI and six reported stroke. No significant differences in the incidence of MI or stroke were found between different antipsychotic drugs or between APs and placebo. However, the rate of CV death was significantly higher with with sertindole than with risperidone (odds ratio 2.56; 95% CI 1.33, 5.0). "The present meta-analysis, which collects all available evidence from clinical trials, confirms that APs have a relevant metabolic impact, leading to an increase in estimated CV risk . . . In addition, different APs are not metabolically equivalent," concluded the authors. "Long-term metabolic and CV effects of AP drugs deserve to be studied more extensively, in order to allow clinicians to balance efficacy and safety when choosing a specific AP treatment," they said. Rotella F, et al. Long-term metabolic and cardiovascular effects of antipsychotic drugs. A meta-analysis of randomized controlled trials. European Neuropsychopharmacology : 803449803 6 Jan 2020. Available from: URL: http://doi.org/10.1016/j.euroneuro.2019.12.118
0114-9954/20/1788-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 25 Jan 2020 No. 1788
Data Loading...
